rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CLLS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      What Cellectis (CLLS) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceCLLS
      Earnings call transcript: Cellectis Q3 2026 loss widens as revenue misses forecast
      Nov 13Investing.comCLLS
      Cellectis ADR earnings missed by $0.42, revenue fell short of estimates
      Nov 13Investing.comCLLS
      Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
      Nov 13Yahoo FinanceCLLS
      Cellectis to Report Third Quarter Financial Results on November 12, 2026
      Nov 9Yahoo FinanceCLLS
      Monthly information on share capital and company voting rights
      Nov 4Yahoo FinanceCLLS
      Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
      Oct 27Yahoo FinanceCLLS
      Monthly information on share capital and company voting rights
      Oct 6Yahoo FinanceCLLS
      Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
      Oct 1Yahoo FinanceCLLS
      Cellectis at Stifel 2026 Virtual Cardiometabolic Forum: pivot to in vivo editing
      Sep 30Investing.comCLLSSF
      Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?

      Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11. It will exit internal development of lasme-cel and eti-cel, seek partners for those cancer therapies, and prioritize two preclinical programs for severe lipid disorders. The shift moves the internal pipeline toward in vivo treatment, delivering editing machinery directly […]

      Sep 17Yahoo FinanceCLLS
      Cellectis stock tumbles after Barclays double downgrade
      Sep 16Investing.comCLLSBCS
      Cellectis Stock: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

      Cellectis pivots to in vivo gene editing, exiting ex-vivo CAR-T programs due to shrinking commercial opportunities. Read why CLLS stock is a hold.

      Sep 16Seeking AlphaCLLS
      Barclays cuts Cellectis stock rating on gene editing concerns
      Sep 16Investing.comCLLS
      Barclays Downgrades Cellectis to Underweight From Overweight, Adjusts PT to $1.30 From $9
      Sep 16Yahoo FinanceCLLS
      Cellectis stock downgraded at Citizens (CLLS:NASDAQ)
      Sep 15Seeking AlphaCLLS
      This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
      Sep 15BenzingaCLLSRBBNBSBR
      CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
      Sep 15Yahoo FinanceCLLS
      Citizens downgrades Cellectis stock rating on strategy shift
      Sep 15Investing.comCLLS
      Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development

      Cellectis is shifting its development strategy toward in vivo gene editing after reporting preclinical proof-of-concept for. HEAL-101 and.

      Sep 14Yahoo FinanceCLLS
      Nasdaq Down Over 200 Points; Cellectis Shares Plunge
      Sep 14BenzingaCLLSSCNI
      What's Going On With Cellectis Stock Monday? - Cellectis (NASDAQ:CLLS)
      Sep 14BenzingaCLLS
      Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
      Sep 14BenzingaBDRXCLLSGLW
      Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

      Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

      Sep 14Yahoo FinanceCLLS
      Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company

      Cellectis (CLLS) shares were down nearly 40% in Monday trading after the company said it will realig

      Sep 14Yahoo FinanceCLLS
      Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

      Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NE

      Sep 13Yahoo FinanceCLLS
      Cellectis Plans September 14 Business Update Webcast for Global Investors

      Detailed price information for Cellectis Romainville Ord (CMVLF) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailCLLS
      Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

      NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. Conference Call and Webcast Details: September 14, 2026 English-language at 8:00 a.m. ET. / 2:00 p.m. CET Webcast link:https://viavid.

      Sep 11Yahoo FinanceCLLS
      Cellectis Updates Share Capital and Voting Rights as of August 31, 2026

      Tipranks Press Release.

      Sep 4The Globe and MailCLLS
      Monthly information on share capital and company voting rights

      (Article 223-16 of General Regulation of the French financial markets authority)PARIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights08/31/2026100,718,974105,568,956 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 7

      Sep 3Yahoo FinanceCLLS
      Cellectis Announces Participation in Upcoming Investor Conferences

      NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference – Boston, MASeptember 10, 2026 Baird 2026 Global Healthcare Conference – New YorkSeptember 15, 2026Company presentation at 12:50 - 1:

      Sep 1Yahoo FinanceCLLS
      Cellectis: 'Hold' Lasme-Cel Q4 2026 Catalyst And Eti-Cel Backup Candidate (NASDAQ:CLLS)
      Aug 25Seeking AlphaCLLS

      This is the newest page. Registered accounts read further back.